Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maxim Plans To File Maxamine Malignant Melanoma NDA By Mid-2000

Executive Summary

Maxim is targeting a mid-2000 NDA filing for its malignant melanoma immunotherapy Maxamine, which will be followed by European regulatory applications, Maxim CEO Larry Stambaugh told a Burns McClellan/Petkevich & Partners analyst meeting in London Oct. 6.

You may also be interested in...



Maxim Maxamine

Phase III study of histamine dihydrochloride in combination with interleukin-2 for the treatment of malignant melanoma presented June 2 at a melanoma meeting in Pittsburgh. Maxamine significantly improved survival compared to IL-2 monotherapy in a prespecified subset of patients with liver metastases. For the 129 patients with liver metastases, median survival was 287 days in the Maxamine group, compared to 154 days for the control group. In the total group of 305 patients, median survival was 272 days, compared to 245 days for the control group, not a statistically significant difference. Patients who completed two courses of therapy did have a statistically significant difference in survival from the control group, however, as did patients who were at treatment centers experienced with the regimen. The company plans to file an NDA mid-summer (1"The Pink Sheet" Oct. 18, p. 16)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS035007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel